Hims & Hers Q2 revenue drop shakes stock—Hims crashes 11% after first-ever revenue decline, is the weight-loss drug hype finally fading?
Synopsis Hims & Hers stock dropped a sharp 11% after the company missed Q2 2025 revenue estimates, raising concerns about its booming weight-loss drug business. While year-over-year sales jumped 73%, revenue fell sequentially for the first time, causing investor worry. The company brought in $544.8 million, short of forecasts, with much of it tied to its GLP-1 obesity drug offerings. Hims & Hers Health (NYSE: HIMS), the fast-growing telehealth company known for its personalized care plans and buzzy entry into the weight-loss market, saw its stock drop by over 11% after reporting second-quarter 2025 earnings. While revenue jumped 73% year-over-year, the company missed Wall Street expectations and posted its first-ever sequential revenue decline, raising questions about the future of its GLP-1 obesity drug business.
ADVERTISEMENT Despite its rapid annual growth, Hims & Hers posted Q2 revenue of $544.8 million, missing the analyst estimate of $552 million. The real concern? Revenue dropped from $586 million in Q1, marking the first quarter-over-quarter decline since the company went public.
The stock currently trades at $63.35, regaining some ground after hitting an intraday low of $54.82. Despite opening at $64.00, it remains volatile, with an intraday high of $65.54.
ALSO READ: Bullish IPO debut: Peter Thiel-backed crypto giant targets $4.2B valuation—is the new crypto wave knocking on Wall Street's door? The market reacted sharply to the company's revenue miss—$544.8 million vs. $552 million expected—even though earnings per share beat expectations and subscriber numbers remained strong. Most of the company's revenue stemmed from its GLP-1-based obesity and diabetes treatments, a booming but increasingly scrutinized business segment.
ALSO READ: Palantir stock soars after $1B Q2 earnings crush forecasts as AI demand fuels 110% YTD surge—now S&P 500's top performer
ADVERTISEMENT With regulatory pressures, lawsuits from Novo Nordisk, and tighter FDA rules on compounded semaglutide, Hims faces headwinds in its fastest-growing segment. However, with a market cap of over $6.5 billion, a P/E ratio of 39.93, and forward-looking confidence via its Zava acquisition, the company is still betting big on growth in both the U.S. and Europe. Current Price : $63.35
: $63.35 Day Range : $54.82 – $65.54
: $54.82 – $65.54 Open : $64.00
: $64.00 Market Cap: $6.56 Billion P/E Ratio : 39.93
: 39.93 Volume: 35.5M Investors were caught off guard, as the slowdown came amid soaring demand for weight-loss drugs like semaglutide, a compound similar to the active ingredient in Wegovy and Ozempic.
ADVERTISEMENT
On the profit front, Hims reported an adjusted EPS of $0.19, beating the Street's expectation of $0.15. However, the revenue miss overshadowed this earnings win. Investors appeared more concerned about the underlying business momentum, particularly in the obesity treatment space, which has been a major driver of Hims' recent growth.
ADVERTISEMENT
Hims' biggest growth story in recent quarters has been its expansion into GLP-1 weight-loss treatments, which brought in around $190 million in Q2 alone. However, a few red flags have emerged: Regulatory uncertainty : With the FDA rolling back flexibility on compounded versions of semaglutide, questions are mounting about how long Hims can rely on this segment for revenue.
: With the FDA rolling back flexibility on of semaglutide, questions are mounting about how long Hims can rely on this segment for revenue. Legal challenges : The company recently ended its supply relationship with Novo Nordisk , the maker of Wegovy, and is now facing lawsuits over how it marketed compounded alternatives.
: The company recently ended its supply relationship with , the maker of Wegovy, and is now facing lawsuits over how it marketed compounded alternatives. Competitive pressure: Big players like Eli Lilly and Novo Nordisk are dominating the branded drug market, making it harder for telehealth companies offering generics to compete on pricing and trust. Despite the Q2 shortfall, Hims & Hers stuck to its full-year outlook. The company reaffirmed its 2025 guidance of $2.3 billion to $2.4 billion in revenue and $295 million to $335 million in adjusted EBITDA.
ADVERTISEMENT A big reason? The Zava acquisition, a European telehealth platform, which is expected to contribute around $50 million in new revenue this year. This suggests Hims is betting heavily on international growth to offset some of its domestic uncertainty. One bright spot in the report was Hims' growing subscriber base. The company now serves over 2.4 million active subscribers, with nearly 70% enrolled in personalized treatment plans that span weight loss, hair care, sexual health, and mental wellness. CEO Andrew Dudum emphasized that the company is leaning deeper into its long-term strategy of personalized digital healthcare, aiming to build loyalty and customer lifetime value across multiple product categories. If you're following Hims & Hers stock or investing in telehealth companies focused on the obesity drug boom, here are four key things to monitor: Future of compounded GLP-1s: Regulatory and legal outcomes could limit Hims' ability to sell compounded semaglutide at scale. Profitability trends: Will margins hold up as more competition floods the market and Hims scales its personalized offerings? Subscriber growth and retention: Continued engagement in non-weight loss categories will be key to long-term stability. Zava integration: The success or failure of this acquisition could make or break Hims' international ambitions. Hims & Hers Health has come a long way as a digital-first wellness brand with a bold strategy around weight-loss drugs and personalized healthcare. But the 11% stock drop shows investor sentiment is shifting, especially as its flagship obesity business faces regulatory hurdles and supply uncertainty. For now, the company's strong year-over-year growth and firm 2025 guidance offer some reassurance. But with rising competition, tighter FDA rules, and legal pressure, Hims will need to prove that its success isn't just tied to a single product wave—but a durable, trusted digital care ecosystem. What caused Hims & Hers stock to fall 11% after Q2 earnings? The company missed revenue estimates and saw its first-ever sequential drop in sales.
Is the Hims weight-loss drug business facing trouble in 2025? Yes, due to FDA scrutiny and legal issues around compounded semaglutide.
(You can now subscribe to our Economic Times WhatsApp channel)
(Catch all the US News, UK News, Canada News, International Breaking News Events, and Latest News Updates on The Economic Times.)
Download The Economic Times News App to get Daily International News Updates.
NEXT STORY
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
28 minutes ago
- Economic Times
Sri Lotus Developers shares to debut today. GMP signals mild listing gains
Sri Lotus Developers is set to list on the BSE and NSE on August 6, with a strong GMP indicating a listing price around Rs 177. The IPO, oversubscribed 74.10 times, saw significant interest from QIBs, NIIs, and retail investors. Proceeds will fund ongoing projects, and the company reported robust FY25 revenue and profit growth. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Shares of Sri Lotus Developers are set to debut on the BSE and NSE on August 6 after a robust IPO subscription. Ahead of the listing, the GMP on the shares of the company in the unlisted market is around 18%. This places the expected listing price at around Rs 177 per share against the issue price of Rs 150, reflecting healthy demand among Rs 792 crore IPO, entirely a fresh issue of 5.28 crore shares, was open for bidding from July 30 to August 1. The issue drew overwhelming interest from all categories of investors, closing with an overall subscription of 74.10 Qualified Institutional Buyers (QIB) segment led the charge with a subscription of 175.61 times, followed by Non-Institutional Investors (61.82 times) and retail investors (21.77 times).Sri Lotus Developers, a Mumbai-based real estate company focused on ultra-luxury and luxury residential and commercial redevelopment projects in the city's affluent western suburbs, has positioned itself as a niche player in a competitive of June 2025, it holds a developable area of 0.93 million square feet and boasts a project pipeline that includes four completed projects, five ongoing, and eleven upcoming IPO proceeds are earmarked primarily for investments in its subsidiaries to fund three ongoing marquee projects — Amalfi, The Arcadian, and Varun — with Rs 550 crore allocated towards development costs. The remaining funds will be used for general corporate purposes. The company follows an asset-light model, partnering with landowners through development agreements, allowing it to maintain healthy cash terms of financial performance, the company has shown healthy growth. Revenue for FY25 stood at Rs 569.28 crore, up 22% from the previous year, while profit after tax more than doubled to Rs 227.89 the IPO oversubscription and strong grey market signals, all eyes are now on the stock's performance on August 6. While the premium suggests listing gains, long-term investors will be watching how the company delivers on its pipeline and manages execution in Mumbai's competitive luxury housing market.(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)
News18
36 minutes ago
- News18
RBI MPC Meeting August 2025 Live Updates: Will Sanjay Malhotra Announce Another Repo Rate Cut Or Status Quo?
RBI Monetary Policy Committee Meeting, Repo Rate Cut Live Updates: RBI Governor Sanjay Malhotra is set to announce the Monetary Policy Committee's decision on interest rates in the country, at 10 am today. Though most economists expect the central bank to keep the repo rate unchanged, several say that the RBI MPC might announce a final 25-basis-point rate cut before an extended status quo. The Reserve Bank of India's (RBI) Monetary Policy Committee (MPC), led by Governor Sanjay Malhotra, began its three-day deliberation on Monday, August 4. It concludes today, August 6. The six-member MPC includes Governor Sanjay Malhotra, Deputy Governor Poonam Gupta, Executive Director Rajiv Ranjan, and three external members: Nagesh Kumar, Saugata Bhattacharya, and Ram Singh. In the previous policy review in June 2025, the RBI MPC had announced a surprise 50 basis points repo rate cut, bringing the key policy rate down to 5.5%, and a 100-bps CRR reduction as the RBI signalled confidence in the easing of price pressures amid a supportive global and domestic backdrop. The RBI has cut the repo rate by 100 bps in three consecutive rate cuts. India's retail inflation, based on the Consumer Price Index (CPI), declined to 2.1 per cent in June 2025, the latest available data. It is the lowest inflation print after January 2019. The CPI-based inflation had stood at 2.82 per cent in May 2025 and 5.08 per cent in June 2024. The RBI is mandated to keep inflation at 4%, with a tolerance band of (-/+) 2%. In June 2025 policy, the RBI revised its retail inflation projection for FY26 to 3.7%, down from its earlier estimate of 4%. This marks the lowest average retail inflation forecast by the central bank in recent years.
Time of India
44 minutes ago
- Time of India
Sri Lotus Developers shares to debut today. GMP signals mild listing gains
Shares of Sri Lotus Developers are set to debut on the BSE and NSE on August 6 after a robust IPO subscription. Ahead of the listing, the GMP on the shares of the company in the unlisted market is around 18%. This places the expected listing price at around Rs 177 per share against the issue price of Rs 150, reflecting healthy demand among investors. The Rs 792 crore IPO, entirely a fresh issue of 5.28 crore shares, was open for bidding from July 30 to August 1. The issue drew overwhelming interest from all categories of investors, closing with an overall subscription of 74.10 times. The Qualified Institutional Buyers (QIB) segment led the charge with a subscription of 175.61 times, followed by Non-Institutional Investors (61.82 times) and retail investors (21.77 times). Sri Lotus Developers, a Mumbai-based real estate company focused on ultra-luxury and luxury residential and commercial redevelopment projects in the city's affluent western suburbs, has positioned itself as a niche player in a competitive landscape. As of June 2025, it holds a developable area of 0.93 million square feet and boasts a project pipeline that includes four completed projects, five ongoing, and eleven upcoming developments. The IPO proceeds are earmarked primarily for investments in its subsidiaries to fund three ongoing marquee projects — Amalfi, The Arcadian, and Varun — with Rs 550 crore allocated towards development costs. The remaining funds will be used for general corporate purposes. The company follows an asset-light model, partnering with landowners through development agreements, allowing it to maintain healthy cash flows. In terms of financial performance, the company has shown healthy growth. Revenue for FY25 stood at Rs 569.28 crore, up 22% from the previous year, while profit after tax more than doubled to Rs 227.89 crore. With the IPO oversubscription and strong grey market signals, all eyes are now on the stock's performance on August 6. While the premium suggests listing gains, long-term investors will be watching how the company delivers on its pipeline and manages execution in Mumbai's competitive luxury housing market.
